KROSKROS
3달 전보다 -11.7%
세로선 = 임상·딜 이벤트 · 차트 위에서 스크롤하면 확대·축소, 확대 중엔 가로로 넘겨볼 수 있어요
TGF-베타 신호 장애 관련 조직 손상을 개선하는 단백질 치료제를 개발해요.
The company is focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-ß, family of proteins. They are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues. By leveraging this understanding, they have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients.
진행 중인 임상과 AI 예측
- Phase 2KER-065 듀센 근이영양증 치료 임상시작 전Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy59%
- Phase 2KER-012 폐동맥고혈압 병용 치료 임상중단A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).84%
- Phase 2KER-047 철분결핍성 빈혈 치료 안전성 임상철회A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).33%
성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.
최근 이벤트
- 기술 수출11월 5일오를 것 같아요
다케다제약과 엘리터셉트(KER-050) 글로벌 라이선스 계약을 맺었어요.